UroGen Pharma (URGN) Free Cash Flow (2017 - 2026)

UroGen Pharma (URGN) has reported Free Cash Flow for 10 consecutive years, with -$47.6 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow fell 13.97% year-over-year to -$47.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$172.9 million (down 62.57% YoY) and the FY2025 annual result came in at -$167.0 million, down 75.22% from the prior year.
• Free Cash Flow declined to -$47.6 million in Q1 2026 per URGN's latest filing, from -$36.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for URGN reached as high as -$13.0 million in Q4 2023 and fell as low as -$48.2 million in Q3 2025.
• A 5-year average of -$27.9 million and a median of -$24.5 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 41.04% — and 2025, when it plunged 165.41%.
• Year by year, Free Cash Flow stood at -$22.0 million in 2022, then soared by 41.04% to -$13.0 million in 2023, then decreased by 6.58% to -$13.8 million in 2024, then slumped by 165.41% to -$36.7 million in 2025, then dropped by 29.74% to -$47.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$47.6 million, -$36.7 million, and -$48.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.